{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:04:54Z","timestamp":1789085094200,"version":"build-2803163510"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.neuropharm.2026.110877","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T17:10:50Z","timestamp":1770657050000},"page":"110877","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["P2X7 receptors as targets for neuroprotection"],"prefix":"10.1016","volume":"289","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5265-1361","authenticated-orcid":false,"given":"Victoria","family":"Maneu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio G.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2026.110877_bib1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bcp.2017.12.021","article-title":"The P2X7 receptor: a main player in inflammation","volume":"151","author":"Adinolfi","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.110877_bib2","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/nn2014","article-title":"Local self-renewal can sustain CNS microglia maintenance and function throughout adult life","volume":"10","author":"Ajami","year":"2007","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.110877_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0165-3806(99)00113-3","article-title":"Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain","volume":"117","author":"Alliot","year":"1999","journal-title":"Dev. Brain Res."},{"key":"10.1016\/j.neuropharm.2026.110877_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01529","article-title":"Modulation of P2X7 receptor during inflammation in multiple sclerosis","volume":"8","author":"Amadio","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuropharm.2026.110877_bib5","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1093\/hmg\/ddt259","article-title":"Ablation of P2X7 receptor exacerbates gliosis and motoneuron death in the SOD1-G93A mouse model of amyotrophic lateral sclerosis","volume":"22","author":"Apolloni","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2026.110877_bib6","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.017038","article-title":"Spinal cord pathology is ameliorated by P2X7 antagonism in SOD1-G93A mouse model of amyotrophic lateral sclerosis","author":"Apolloni","year":"2014","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.neuropharm.2026.110877_bib7","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.4049\/jimmunol.1203262","article-title":"The NADPH oxidase pathway is dysregulated by the P2X7 receptor in the SOD1-G93A microglia model of amyotrophic lateral sclerosis","volume":"190","author":"Apolloni","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.neuropharm.2026.110877_bib8","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.3064","article-title":"P2X7 antagonism using Brilliant Blue G reduces body weight loss and prolongs survival in female SOD1 G93A amyotrophic lateral sclerosis mice","volume":"5","author":"Bartlett","year":"2017","journal-title":"PeerJ"},{"key":"10.1016\/j.neuropharm.2026.110877_bib9","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/bph.12314","article-title":"Pharmacological characterization of a novel centrally permeable <scp>P2X7<\/scp> receptor antagonist: <scp>jnj<\/scp> \u201047965567","volume":"170","author":"Bhattacharya","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.110877_bib10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0031-6997(25)06930-3","article-title":"Purinergic nerves","volume":"24","author":"Burnstock","year":"1972","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2026.110877_bib11","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/med.21710","article-title":"The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases","volume":"40","author":"Calzaferri","year":"2020","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.neuropharm.2026.110877_bib12","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.neuropharm.2014.01.045","article-title":"The P2X7 receptor antagonist Brilliant Blue G attenuates contralateral rotations in a rat model of Parkinsonism through a combined control of synaptotoxicity, neurotoxicity and gliosis","volume":"81","author":"Carmo","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2026.110877_bib13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.tox.2013.04.004","article-title":"Motor neuron dysfunction in a mouse model of ALS: Gender-dependent effect of P2X7 antagonism","volume":"311","author":"Cervetto","year":"2013","journal-title":"Toxicology"},{"key":"10.1016\/j.neuropharm.2026.110877_bib14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neuroscience.2014.08.036","article-title":"Brilliant Blue G improves cognition in an animal model of Alzheimer's disease and inhibits amyloid-\u03b2-induced loss of filopodia and dendrite spines in hippocampal neurons","volume":"279","author":"Chen","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2026.110877_bib15","article-title":"Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder","volume":"2021","author":"Dean","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2026.110877_bib16","doi-asserted-by":"crossref","first-page":"866","DOI":"10.2174\/0929867322666141210155311","article-title":"P2X receptors and inflammation","volume":"22","author":"Di Virgilio","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2026.110877_bib17","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.neurobiolaging.2011.09.040","article-title":"In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer's disease through GSK3\u03b2 and secretases","volume":"33","author":"Diaz-Hernandez","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2026.110877_bib18","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1096\/fj.08-122275","article-title":"Altered P2X7\u2010receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration","volume":"23","author":"D\u00edaz-Hern\u00e1ndez","year":"2009","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2026.110877_bib19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/jnc.13607","article-title":"Neuroinflammation: the devil is in the details","volume":"139","author":"DiSabato","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2026.110877_bib20","first-page":"2289","article-title":"P2X7 receptor antagonist protects retinal ganglion cells by inhibiting microglial activation in a rat chronic ocular hypertension model","volume":"17","author":"Dong","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.neuropharm.2026.110877_bib21","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1124\/jpet.103.059600","article-title":"Mitogen-Activated protein kinase and caspase signaling pathways are required for P2X7 receptor (P2X7R)-Induced Pore Formation in human THP-1 cells","volume":"308","author":"Donnelly-Roberts","year":"2004","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2026.110877_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.neuropharm.2008.06.012","article-title":"[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors","volume":"56","author":"Donnelly-Roberts","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2026.110877_bib23","first-page":"1","article-title":"Inflammatory pathways in parkinson's disease; A BNE microarray Study. Parkinsons","volume":"2012","author":"Durrenberger","year":"2012","journal-title":"Dis"},{"key":"10.1016\/j.neuropharm.2026.110877_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2017.00249","article-title":"P2X7 receptor activation modulates autophagy in SOD1-G93A mouse microglia","volume":"11","author":"Fabbrizio","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.110877_bib25","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.4049\/jimmunol.176.7.3877","article-title":"The P2X7 receptor: a key player in IL-1 processing and release","volume":"176","author":"Ferrari","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.neuropharm.2026.110877_bib26","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3727\/096368917X695227","article-title":"Brilliant blue G, but not fenofibrate, treatment reverts hemiparkinsonian behavior and restores dopamine levels in an animal model of parkinson's disease","volume":"26","author":"Ferrazoli","year":"2017","journal-title":"Cell Transplant."},{"key":"10.1016\/j.neuropharm.2026.110877_bib27","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1096\/fj.14-268714","article-title":"The P2X7 receptor directly interacts with the NLRP3 inflammasome scaffold protein","volume":"29","author":"Franceschini","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2026.110877_bib28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11481-018-9816-3","article-title":"P2X7 receptor antagonist A804598 inhibits inflammation in brain and liver in C57BL\/6J mice exposed to chronic ethanol and high fat diet","volume":"14","author":"Freire","year":"2019","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.110877_bib29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1742-2094-7-33","article-title":"Extracellular ATP and the P2X7receptor in astrocyte-mediated motor neuron death: implications for amyotrophic lateral sclerosis","volume":"7","author":"Gandelman","year":"2010","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2026.110877_bib30","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1194637","article-title":"Fate mapping analysis reveals that adult microglia derive from primitive macrophages","volume":"330","author":"Ginhoux","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2026.110877_bib31","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrd1501","article-title":"Cardiovascular combinations","volume":"3","author":"Glass","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2026.110877_bib32","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.neuint.2010.08.021","article-title":"Temporal expression of P2X7 purinergic receptor during the course of experimental autoimmune encephalomyelitis","volume":"57","author":"Grygorowicz","year":"2010","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2026.110877_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.55782\/ane-2011-1823","article-title":"Expression of purinergic P2X(7) receptor in rat brain during the symptomatic phase of experimental autoimmune encephalomyelitis and after recovery of neurological deficits","volume":"71","author":"Grygorowicz","year":"2011","journal-title":"Acta Neurobiol. Exp."},{"key":"10.1016\/j.neuropharm.2026.110877_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcn.2016.02.003","article-title":"Early P2X7R-related astrogliosis in autoimmune encephalomyelitis","volume":"74","author":"Grygorowicz","year":"2016","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.110877_bib35","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1126\/science.8209258","article-title":"Motor neuron degeneration in mice that Express a Human Cu,Zn superoxide dismutase mutation","volume":"264","author":"Gurney","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2026.110877_bib36","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1126\/science.1056072","article-title":"Principles for the buffering of genetic variation","volume":"291","author":"Hartman IV","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2026.110877_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2025.107106","article-title":"P2RX7 modulates the function of human microglia-like cells and mediates the association of IL18 with Alzheimer's disease traits","volume":"216","author":"Heavener","year":"2025","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2026.110877_bib38","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1124\/jpet.106.111559","article-title":"A-740003 [N-(1-{[(Cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a Novel and Selective P2X7 Receptor Antagonist, Dose-Dependently Reduces Neuropathic Pain in the Rat","volume":"319","author":"Honore","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2026.110877_bib39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1750-1326-6-28","article-title":"Lack of neuroprotection in the absence of P2X7 receptors in toxin-induced animal models of Parkinson's disease","volume":"6","author":"Hracsk\u00f3","year":"2011","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2026.110877_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1713748","article-title":"Targeting the P2X7 receptor in cerebrovascular diseases: from molecular mechanisms to preclinical therapeutic potential","volume":"16","author":"Hu","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.110877_bib41","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/jnci\/djr246","article-title":"Opportunities and challenges in the development of experimental drug combinations for cancer","volume":"103","author":"Humphrey","year":"2011","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.neuropharm.2026.110877_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083475","article-title":"Autophagy in the human placenta throughout gestation","volume":"8","author":"Hung","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2026.110877_bib43","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21m14345","article-title":"Efficacy and safety of AXS-05 (Dextromethorphan-Bupropion) in patients with major depressive disorder","volume":"83","author":"Iosifescu","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2026.110877_bib44","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/jlcr.3206","article-title":"Synthesis and initial preclinical evaluation of the P2X 7 receptor antagonist [ 11 C]A\u2010740003 as a novel tracer of neuroinflammation","volume":"57","author":"Janssen","year":"2014","journal-title":"J. Label. Compd. Radiopharm."},{"key":"10.1016\/j.neuropharm.2026.110877_bib45","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.neurobiolaging.2015.03.015","article-title":"P2X7 receptor is critical in \u03b1-synuclein\u2013mediated microglial NADPH oxidase activation","volume":"36","author":"Jiang","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2026.110877_bib46","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/cmi.2015.95","article-title":"Molecular mechanisms regulating NLRP3 inflammasome activation","volume":"13","author":"Jo","year":"2016","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.neuropharm.2026.110877_bib47","doi-asserted-by":"crossref","first-page":"37350","DOI":"10.1074\/jbc.M707915200","article-title":"Extracellular ATP mediates necrotic cell swelling in SN4741 dopaminergic neurons through P2X7 receptors","volume":"282","author":"Jun","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2026.110877_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10555","article-title":"Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1\u03b2 secretion in response to ATP","volume":"7","author":"Karmakar","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2026.110877_bib49","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.4049\/jimmunol.1402658","article-title":"K+ efflux agonists induce NLRP3 inflammasome activation independently of Ca2+ signaling","volume":"194","author":"Katsnelson","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.neuropharm.2026.110877_bib50","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nrd2195","article-title":"A robustness-based approach to systems-oriented drug design","volume":"6","author":"Kitano","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2026.110877_bib51","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1007\/s11064-017-2383-9","article-title":"Purinergic antagonism prevents mitochondrial dysfunction and behavioral deficits associated with dopaminergic toxicity induced by 6-OHDA in rats","volume":"42","author":"Kumar","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2026.110877_bib52","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1126\/science.7542804","article-title":"Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy","volume":"269","author":"Larder","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2026.110877_bib53","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3858\/emm.2011.43.1.001","article-title":"Microglial P2X 7 receptor expression is accompanied by neuronal damage in the cerebral cortex of the APP swe\/PS1dE9 mouse model of Alzheimer's disease","volume":"43","author":"Lee","year":"2011","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.neuropharm.2026.110877_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.70203","article-title":"Role of P2X7R in retinal diseases: a review","volume":"13","author":"Li","year":"2025","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.neuropharm.2026.110877_bib55","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.expneurol.2012.06.011","article-title":"Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS","volume":"237","author":"Liao","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2026.110877_bib56","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.neulet.2016.07.039","article-title":"Down-regulation of purinergic P2X7 receptor expression and intracellular calcium dysregulation in peripheral blood mononuclear cells of patients with amyotrophic lateral sclerosis","volume":"630","author":"Liu","year":"2016","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2026.110877_bib57","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11302-020-09692-4","article-title":"The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1G93A mice","volume":"16","author":"Ly","year":"2020","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.neuropharm.2026.110877_bib58","doi-asserted-by":"crossref","DOI":"10.34172\/apb.43206","article-title":"Purinergic receptor (P2X7R): a promising anti-parkinson\u2019s drug target","author":"Magham","year":"2024","journal-title":"Adv. Pharmaceut. Bull."},{"key":"10.1016\/j.neuropharm.2026.110877_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112911","article-title":"Combined drug triads for synergic neuroprotection in retinal degeneration","volume":"149","author":"Maneu","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.neuropharm.2026.110877_bib60","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00702-010-0400-0","article-title":"On the role of P2X7 receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X7 receptor antagonist A-438079","volume":"117","author":"Marcellino","year":"2010","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuropharm.2026.110877_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314758","article-title":"Purinergic receptors P2X7 and P2X4 as markers of disease progression in the rd10 mouse model of inherited retinal dystrophy","volume":"23","author":"Mart\u00ednez-Gil","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2026.110877_bib62","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol. Cell"},{"key":"10.1016\/j.neuropharm.2026.110877_bib63","doi-asserted-by":"crossref","first-page":"9525","DOI":"10.1523\/JNEUROSCI.0579-07.2007","article-title":"P2X 7 receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis","volume":"27","author":"Matute","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.110877_bib64","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/01.jnen.0000240470.97295.d3","article-title":"Upregulated expression of purinergic P2X 7 receptor in alzheimer disease and Amyloid-\u03b2 Peptide-Treated microglia and in Peptide-Injected Rat Hippocampus","volume":"65","author":"McLarnon","year":"2006","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2026.110877_bib65","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/glia.22499","article-title":"Human astrocytes express a novel NLRP2 inflammasome","volume":"61","author":"Minkiewicz","year":"2013","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2026.110877_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/srep38499","article-title":"Involvement of P2X7 receptor in neuronal degeneration triggered by traumatic injury","volume":"6","author":"Nadal-Nicolas","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2026.110877_bib67","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bbi.2017.08.015","article-title":"Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer's disease and levodopa-induced dyskinesia","volume":"67","author":"Navarro","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2026.110877_bib68","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1067\/mai.2001.112939","article-title":"Advair: combination treatment with fluticasone propionate\/salmeterol in the treatment of asthma","volume":"107","author":"Nelson","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.neuropharm.2026.110877_bib69","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1146\/annurev.pharmtox.40.1.563","article-title":"Pharmacology of cloned P2X receptors","volume":"40","author":"North","year":"2000","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2026.110877_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2020.567430","article-title":"P2X7 receptor upregulation in Huntington's disease brains","volume":"13","author":"Oll\u00e0","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.110877_bib71","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nature05289","article-title":"A network dysfunction perspective on neurodegenerative diseases","volume":"443","author":"Palop","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2026.110877_bib72","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nature02636","article-title":"Metabolic network analysis of the causes and evolution of enzyme dispensability in yeast","volume":"429","author":"Papp","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2026.110877_bib73","doi-asserted-by":"crossref","first-page":"13309","DOI":"10.1074\/jbc.M209478200","article-title":"P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease","volume":"278","author":"Parvathenani","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2026.110877_bib74","doi-asserted-by":"crossref","first-page":"12489","DOI":"10.1073\/pnas.0902531106","article-title":"Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury","volume":"106","author":"Peng","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2026.110877_bib75","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2337\/db16-0051","article-title":"CD40 in retinal muller cells induces P2X7-Dependent cytokine expression in Macrophages\/Microglia in diabetic mice and development of early experimental diabetic retinopathy","volume":"66","author":"Portillo","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.neuropharm.2026.110877_bib76","series-title":"Handbook of Animal Models in Neurological Disorders","first-page":"81","article-title":"The amyotrophic lateral sclerosis SOD1G93A mouse model and applications: studies into the P2X7 receptor","author":"Puig","year":"2023"},{"key":"10.1016\/j.neuropharm.2026.110877_bib77","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/cne.21964","article-title":"Extracellular ATP induces retinal photoreceptor apoptosis through activation of purinoceptors in rodents","volume":"513","author":"Puthussery","year":"2009","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2026.110877_bib78","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1177\/0269881120914206","article-title":"Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial","volume":"34","author":"Recourt","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2026.110877_bib79","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.neuropharm.2015.05.005","article-title":"Purinergic signaling in retinal degeneration and regeneration","volume":"104","author":"Reichenbach","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2026.110877_bib80","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/362059a0","article-title":"Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis","volume":"362","author":"Rosen","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2026.110877_bib81","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.045732","article-title":"Chronic administration of P2X7 receptor antagonist JNJ-47965567 delays disease onset and progression, and improves motor performance in ALS SOD1G93A female mice","volume":"13","author":"Ruiz-Ruiz","year":"2020","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.neuropharm.2026.110877_bib82","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/WNR.0b013e3283179333","article-title":"Block of purinergic P2X7 receptor is neuroprotective in an animal model of Alzheimer's disease","volume":"19","author":"Ryu","year":"2008","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2026.110877_bib83","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.neuropharm.2017.10.027","article-title":"P2X receptor overexpression induced by soluble oligomers of amyloid beta peptide potentiates synaptic failure and neuronal dyshomeostasis in cellular models of Alzheimer's disease","volume":"128","author":"S\u00e1ez-Orellana","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2026.110877_bib84","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.4049\/jimmunol.0803612","article-title":"Activation of microglia by Amyloid \u03b2 requires P2X7 receptor expression","volume":"182","author":"Sanz","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.neuropharm.2026.110877_bib85","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1742-2094-5-33","article-title":"P2x7 deficiency suppresses development of experimental autoimmune encephalomyelitis","volume":"5","author":"Sharp","year":"2008","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2026.110877_bib86","article-title":"Correction: an improved method for P2X7R antagonist screening","volume":"10","author":"Soares-Bezerra","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2026.110877_bib87","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3899\/jrheum.110874","article-title":"Efficacy and safety of CE-224,535, an antagonist of P2X 7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate","volume":"39","author":"Stock","year":"2012","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.neuropharm.2026.110877_bib88","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3892\/mmr.2016.6070","article-title":"Inhibiting purinergic P2X7 receptors with the antagonist brilliant blue G is neuroprotective in an intranigral lipopolysaccharide animal model of Parkinson's disease","volume":"15","author":"Wang","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.neuropharm.2026.110877_bib89","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1007\/s10753-015-0189-y","article-title":"P2X7 receptor expression in peripheral blood monocytes is correlated with plasma C-Reactive protein and cytokine levels in patients with type 2 diabetes mellitus: a preliminary report","volume":"38","author":"Wu","year":"2015","journal-title":"Inflammation"},{"key":"10.1016\/j.neuropharm.2026.110877_bib90","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5520644","article-title":"P2X7 receptor antagonist attenuates retinal inflammation and neovascularization induced by oxidized low-density lipoprotein","author":"Yang","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.neuropharm.2026.110877_bib91","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2377-6-12","article-title":"COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells\/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord","volume":"6","author":"Yiangou","year":"2006","journal-title":"BMC Neurol."},{"key":"10.1016\/j.neuropharm.2026.110877_bib92","article-title":"Neuroinflammation in retinitis pigmentosa: therapies targeting the innate immune system","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082600050X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082600050X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T07:57:05Z","timestamp":1779004625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839082600050X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":92,"alternative-id":["S002839082600050X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.110877","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"P2X7 receptors as targets for neuroprotection","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.110877","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110877"}}